SCHEMBL30859934

SCHEMBL30859934

CNCCC(=O)N1CC2CCC(C1)N2c1ccc(C#N)cn1

nearest known ligand 0.56

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
CHRM1 P11229 6/20 0.56
CHRM2 P08172 3/20 0.56
CHRM4 P08173 2/20 0.56
CHRM3 P20309 1/20 0.56
KCNH2 Q12809 1/20 0.56
PANK3 Q9H999 4/20 0.43
DPP4 P27487 2/20 0.41
USP30 Q70CQ3 1/20 0.41
CHRM5 P08912 1/20 0.40
PARP1 P09874 3/20 0.40
IRAK4 Q9NWZ3 1/20 0.40
DPP7 Q9UHL4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23216903 0.89 CHRM4 (0.55) CHRM1CHRM2CHRM4CHRM3KCNH2
SCHEMBL23215090 0.87 CHRM1 (0.61) CHRM1CHRM2CHRM4CHRM3KCNH2
SCHEMBL23215018 0.86 CHRM1 (0.55) CHRM1CHRM2CHRM4CHRM3KCNH2
Hydrochloric Acid SCHEMBL29664720 0.86 CHRM1 (0.60) CHRM1CHRM2CHRM4CHRM3KCNH2
SCHEMBL23231761 0.85 CHRM1 (0.52) CHRM1CHRM2CHRM4CHRM3KCNH2
SCHEMBL30265167 0.85 CHRM1 (0.52) CHRM1CHRM2CHRM4CHRM3KCNH2
SCHEMBL23231824 0.84 CHRM1 (0.51) CHRM1CHRM2CHRM4CHRM3KCNH2
SCHEMBL23231394 0.84 CHRM1 (0.55) CHRM1CHRM2CHRM4CHRM3KCNH2
SCHEMBL30859896 0.84 CHRM1 (0.56) CHRM1CHRM2CHRM4CHRM3KCNH2
SCHEMBL23231311 0.83 CHRM1 (0.50) CHRM1CHRM2CHRM4CHRM3KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260109686-A1 PYRIDAZIN-3(2H)-ONE AND PYRIDIN-2(1H)-ONE PARP INHIBITOR COMPOUNDS AZKARRA THERAPEUTICS, INC. (US) 2026-04-23 US disclosed
EP-4594314-A1 PYRIDAZIN-3(2H)-ONE AND PYRIDIN-2(1H)-ONE PARP INHIBITOR COMPOUNDS Azkarra Therapeutics, Inc. (US) 2025-08-06 EP disclosed
CN-119968364-A Pyridazin-3 (2H) -one and pyridin-2 (1H) -one PARP inhibitor compounds 阿兹卡拉疗法公司 2025-05-09 CN disclosed
WO-2024073133-A1 PYRIDAZIN-3(2H)-ONE AND PYRIDIN-2(1H)-ONE PARP INHIBITOR COMPOUNDS AZKARRA THERAPEUTICS, INC. (US) 2024-04-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260109686-A1 PYRIDAZIN-3(2H)-ONE AND PYRIDIN-2(1H)-ONE PARP INHIBITOR COMPOUNDS PARP2, PARP1, PARP11 CHRM1 3098/4885CHRM2 3263/4885CHRM4 4073/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.